| Dr Kevin John Bruen, MD | |
|
2900 12th Ave N, Suite 400e, Billings, MT 59101-7506 | |
| (406) 238-6820 | |
| (406) 238-6838 |
| Full Name | Dr Kevin John Bruen |
|---|---|
| Gender | Male |
| Speciality | Vascular Surgery |
| Experience | 22 Years |
| Location | 2900 12th Ave N, Billings, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427221886 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Vincent Healthcare | Billings, MT | Hospital |
| Cody Regional Health | Cody, WY | Hospital |
| Bozeman Health Deaconess Hospital | Bozeman, MT | Hospital |
| St James Healthcare | Butte, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scl Health Medical Group - Billings Llc | 9638491574 | 219 |
| Scl Health Medical Group - Billings Llc | 9638491574 | 219 |
News Archive
The State of New Jersey today announced that DSM, with its North American headquarters in Parsippany, NJ, is a winner of the 2014 Governor's Environmental Excellence Award in the Healthy & Sustainable Business category.
A new antibiotic hailed as the "last line of defense" in the battle against drug-resistant superbugs such as MSRA and VRE is taking the next step in development thanks to a UK Government grant of almost £500,000.
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office.
CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) has notified the Company that its new biologic license application (BLA) for ocriplasmin intravitreal injection will be discussed at the Dermatologic and Ophthalmic Drugs Advisory Committee scheduled for July 26, 2012.
› Verified 3 days ago
| Entity Name | Scl Health Montana |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083655997 PECOS PAC ID: 3476457714 Enrollment ID: O20031229000380 |
News Archive
The State of New Jersey today announced that DSM, with its North American headquarters in Parsippany, NJ, is a winner of the 2014 Governor's Environmental Excellence Award in the Healthy & Sustainable Business category.
A new antibiotic hailed as the "last line of defense" in the battle against drug-resistant superbugs such as MSRA and VRE is taking the next step in development thanks to a UK Government grant of almost £500,000.
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office.
CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) has notified the Company that its new biologic license application (BLA) for ocriplasmin intravitreal injection will be discussed at the Dermatologic and Ophthalmic Drugs Advisory Committee scheduled for July 26, 2012.
› Verified 3 days ago
| Entity Name | Scl Health Medical Group - Billings Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508289703 PECOS PAC ID: 9638491574 Enrollment ID: O20141204001495 |
News Archive
The State of New Jersey today announced that DSM, with its North American headquarters in Parsippany, NJ, is a winner of the 2014 Governor's Environmental Excellence Award in the Healthy & Sustainable Business category.
A new antibiotic hailed as the "last line of defense" in the battle against drug-resistant superbugs such as MSRA and VRE is taking the next step in development thanks to a UK Government grant of almost £500,000.
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office.
CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) has notified the Company that its new biologic license application (BLA) for ocriplasmin intravitreal injection will be discussed at the Dermatologic and Ophthalmic Drugs Advisory Committee scheduled for July 26, 2012.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kevin John Bruen, MD 2900 12th Ave N, Suite 400e, Billings, MT 59101-7506 Ph: (406) 238-6820 | Dr Kevin John Bruen, MD 2900 12th Ave N, Suite 400e, Billings, MT 59101-7506 Ph: (406) 238-6820 |
News Archive
The State of New Jersey today announced that DSM, with its North American headquarters in Parsippany, NJ, is a winner of the 2014 Governor's Environmental Excellence Award in the Healthy & Sustainable Business category.
A new antibiotic hailed as the "last line of defense" in the battle against drug-resistant superbugs such as MSRA and VRE is taking the next step in development thanks to a UK Government grant of almost £500,000.
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office.
CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) has notified the Company that its new biologic license application (BLA) for ocriplasmin intravitreal injection will be discussed at the Dermatologic and Ophthalmic Drugs Advisory Committee scheduled for July 26, 2012.
› Verified 3 days ago
Thomas Mitchell Gallagher, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2510 17th St W, Billings, MT 59102 Phone: 406-245-3238 Fax: 406-248-6814 | |
Fred V Schneider, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 2900 12th Ave N, Ste 502e, Billings, MT 59101 Phone: 406-245-6982 Fax: 406-245-1539 | |
Robert J Hancock, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Nolan Mann, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 2800 10th Ave N, Billings, MT 59101 Phone: 406-238-2500 | |
Scott H. Dull, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Jeffrey R Balison, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 2345 King Ave W, Billings, MT 59102 Phone: 406-651-5670 | |
Bret Murray, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 |